← Leaderboards
Maurizio Fava
Massachusetts General Hospital
$41,478,557
Attributed
$55,543,109
Total exposure
15
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $15.3M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$55,543,109 · 15
By mechanism
OT2$19,316,294 · 1
R01$15,175,627 · 5
U24$9,428,639 · 1
N01$3,331,319 · 1
U01$3,193,254 · 1
R25$2,699,824 · 2
Top collaborators
- Shelly F Greenfield14 shared
- Robert R Edwards6 shared
- James P. Rathmell6 shared
- Cristina Cusin5 shared
- A Eden Evins5 shared
- Diego A. Pizzagalli5 shared
- Robert H Dworkin3 shared
- Karen K Miller3 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Jonathan Edward Alpert$3,009,792
- Cristina Cusin$1,760,816
- A Eden Evins$20,295,171
- X X$12,589,515
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsAdultClinical ResearchDesignResponsePlacebosSiteInterestPharmaceutical PreparationsTrainingResearch PersonnelProgramsHospitalsEnrollmentLeadershipFundingReportingMemberMental DepressionFutureResourcesMentorshipFosteringNeurosciences
Grant awards (74)
EPPIC-Net Pain Research - Application for Clinical Trial and Related Activities (OT2)$1,121,347
OT2 · FY2025 · NS · contact PI
Fostering Research Mentorship and Training During Psychiatry Residency$216,000
R25 · FY2025 · MH · contact PI
EPPIC-Net Pain Research - Application for Clinical Trial and Related Activities (OT2)$2,752,607
OT2 · FY2024 · NS · contact PI
Fostering Research Mentorship and Training During Psychiatry Residency$216,000
R25 · FY2024 · MH · contact PI
EPPIC-Net Pain Research - Application for Clinical Trial and Related Activities (OT2)$2,226,370
OT2 · FY2023 · NS · contact PI
Clinical Coordinating Center for the Health Initiative in Early Phase Pain Investigation Clinical Network$597,916
U24 · FY2023 · NS · contact PI
Clinical Coordinating Center for the Health Initiative in Early Phase Pain Investigation Clinical Network$2,030,400
U24 · FY2022 · NS · contact PI
EPPIC-Net Pain Research - Application for Clinical Trial and Related Activities (OT2)$200,000
OT2 · FY2022 · NS · contact PI
Fostering Research Mentorship & Training during Psychiatry Residency Supplement$15,768
R25 · FY2022 · MH · contact PI
EPPIC-Net Pain Research - Application for Clinical Trial and Related Activities (OT2)$13,015,970
OT2 · FY2021 · NS · contact PI
Clinical Coordinating Center for the Health Initiative in Early Phase Pain Investigation Clinical Network$1,969,304
U24 · FY2021 · NS · contact PI
Fostering Research Mentorship and Training During Psychiatry Residency$192,367
R25 · FY2021 · MH · contact PI
Clinical Coordinating Center for the Health Initiative in Early Phase Pain Investigation Clinical Network$62,704
U24 · FY2021 · NS · contact PI
Fostering Research Mentorship and Training During Psychiatry Residency$15,120
R25 · FY2021 · MH · contact PI
Clinical Coordinating Center for the Health Initiative in Early Phase Pain Investigation Clinical Network$2,012,720
U24 · FY2020 · NS · contact PI
Fostering Research Mentorship and Training During Psychiatry Residency$195,550
R25 · FY2020 · MH · contact PI
Fostering Research Mentorship and Training During Psychiatry Residency$15,120
R25 · FY2020 · MH · contact PI
Clinical Coordinating Center for the Health Initiative in Early Phase Pain Investigation Clinical Network$2,755,595
U24 · FY2019 · NS · contact PI
Neurobiological Underpinnings of Placebo Response in Depression$730,710
R01 · FY2019 · MH · contact PI
Fostering Research Mentorship and Training During Psychiatry Residency$198,733
R25 · FY2019 · MH · contact PI
Fostering Research Mentorship and Training during Psychiatry Residency: Supplement for Diversity and Inclusion$15,120
R25 · FY2019 · MH · contact PI
Neurobiological Underpinnings of Placebo Response in Depression$755,429
R01 · FY2018 · MH · contact PI
Fostering Research Mentorship and Training During Psychiatry Residency$201,915
R25 · FY2018 · MH · contact PI
Neurobiological Underpinnings of Placebo Response in Depression$755,429
R01 · FY2017 · MH · contact PI
RAPIDLY-ACTING TREATMENTS FOR SEVERE TREATMENT RESISTANT DEPRESSION (RAPID)$288,473
N01 · FY2017 · MH · contact PI
Fostering Research Mentorship and Training During Psychiatry Residency$205,097
R25 · FY2017 · MH · contact PI
RAPIDLY-ACTING TREATMENTS FOR SEVERE TREATMENT RESISTANT DEPRESSION (RAPID)$1,768,299
N01 · FY2016 · MH · contact PI
Neurobiological Underpinnings of Placebo Response in Depression$758,984
R01 · FY2016 · MH · contact PI
Proof-of-Concept Trial of an Alpha-7 Nicotinic Agonist for Nicotine Dependence$1,086,478
R01 · FY2015 · DA
Neurobiological Underpinnings of Placebo Response in Depression$871,370
R01 · FY2015 · MH · contact PI
IGF::OT::IGF RAPIDLY-ACTING TREATMENTS FOR TREATMENT-RESISTANT DEPRESSION (RAPID)$513,036
N01 · FY2015 · MH · contact PI
RAPIDLY-ACTING TREATMENTS FOR SEVERE TREATMENT RESISTANT DEPRESSION$269,575
N01 · FY2015 · MH · contact PI
1/2-Collaborative Study: Testosterone Antidepressant Augmentation in Women$261,000
R34 · FY2015 · MH
Fostering Research Mentorship and Training During Psychiatry Residency$241,515
R25 · FY2015 · MH · contact PI
RAPIDLY-ACTING TREATMENTS FOR SEVERE TREATMENT RESISTANT DEPRESSION (RAPID)$135,426
N01 · FY2015 · MH · contact PI
Proof-of-Concept Trial of an Alpha-7 Nicotinic Agonist for Nicotine Dependence$1,179,683
R01 · FY2014 · DA
1/2-Collaborative Study: Testosterone Antidepressant Augmentation in Women$261,000
R34 · FY2014 · MH
Fostering Research Mentorship and Training During Psychiatry Residency$241,515
R25 · FY2014 · MH · contact PI
IGF::OT::IGF RAPIDLY-ACTING TREATMENTS FOR TREATMENT-RESISTANT DEPRESSION (RAPID)$143,962
N01 · FY2014 · MH · contact PI
RAPIDLY-ACTING TREATMENTS FOR TREATMENT-RESISTANT DEPRESSION (RAPID)$109,398
N01 · FY2014 · MH · contact PI
Proof-of-Concept Trial of an Alpha-7 Nicotinic Agonist for Nicotine Dependence$1,131,580
R01 · FY2013 · DA
1/2-Collaborative Study: Testosterone Antidepressant Augmentation in Women$261,000
R34 · FY2013 · MH
Fostering Research Mentorship and Training During Psychiatry Residency$231,854
R25 · FY2013 · MH · contact PI
3/3-Efficacy and Tolerability of Riluzole in Treatment-Resistant Depression$220,189
R01 · FY2013 · MH · contact PI
Proof-of-Concept Trial of an Alpha-7 Nicotinic Agonist for Nicotine Dependence$1,215,914
R01 · FY2012 · DA
3/3-Efficacy and Tolerability of Riluzole in Treatment-Resistant Depression$268,479
R01 · FY2012 · MH · contact PI
Fostering Research Mentorship and Training During Psychiatry Residency$241,515
R25 · FY2012 · MH · contact PI
3/3-Efficacy and Tolerability of Riluzole in Treatment-Resistant Depression$235,439
R01 · FY2012 · MH · contact PI
Proof-of-Concept Trial of an Alpha-7 Nicotinic Agonist for Nicotine Dependence$1,277,373
R01 · FY2011 · DA
Fostering Research Mentorship and Training During Psychiatry Residency$256,635
R25 · FY2011 · MH · contact PI
3/3-Efficacy and Tolerability of Riluzole in Treatment-Resistant Depression$241,624
R01 · FY2011 · MH · contact PI
RAPIDLY-ACTING TREATMENTS FOR TREATMENT-RESISTANT DEPRESSION (RAPID)$103,150
N01 · FY2011 · MH · contact PI
Drug Discovery Group for Nicotine Dependence Treatment$549,947
U01 · FY2010 · DA · contact PI
3/3-Efficacy and Tolerability of Riluzole in Treatment-Resistant Depression$245,490
R01 · FY2010 · MH · contact PI
Drug Discovery Group for Nicotine Dependence Treatment$535,800
U01 · FY2009 · DA · contact PI
Controlled Study of SAMe vs.Escitalopram in Major Depressive Disorder$574,955
R01 · FY2008 · AT · contact PI
Drug Discovery Group for Nicotine Dependence Treatment$521,261
U01 · FY2008 · DA · contact PI
Controlled Study of SAMe vs.Escitalopram in Major Depressive Disorder$569,599
R01 · FY2007 · AT · contact PI
Drug Discovery Group for Nicotine Dependence Treatment$517,502
U01 · FY2007 · DA · contact PI
Placebo-Controlled Study of SAMe vs.Escitalopram in MDD$553,010
R01 · FY2006 · AT · contact PI
Placebo-Controlled Study of SAMe vs.Escitalopram in MDD$552,231
R01 · FY2005 · AT
Drug Discovery Group for Nicotine Dependence Treatment$531,041
U01 · FY2005 · DA
Placebo-Controlled Study of SAMe vs.Escitalopram in MDD$545,038
R01 · FY2004 · AT
Drug Discovery Group for Nicotine Dependence Treatment$537,703
U01 · FY2004 · DA
BUPROPION AS AN ADJUNCT TO THE NICOTINE PATCH PLUS CBT$367,395
R01 · FY2003 · DA
BUPROPION AS AN ADJUNCT TO THE NICOTINE PATCH PLUS CBT$356,699
R01 · FY2002 · DA
BUPROPION AS AN ADJUNCT TO THE NICOTINE PATCH PLUS CBT$346,307
R01 · FY2001 · DA
PREDICTION OF OUTCOME DURING FLUOXETINE CONTINUATION$299,845
R10 · FY2001 · MH
PREDICTION OF OUTCOME DURING FLUOXETINE CONTINUATION$482,899
R10 · FY2000 · MH
BEHAVIORAL EFFECTS OF ACUTE TRYPTOPHAN DEPLETION IN DEPRESSED PATIENTS$415,629
M01 · FY2000 · RR
FLUOXETINE, PAROXETINE, &SERTRALINE IN TREAT OF MAJOR DEPRESSION$415,629
M01 · FY2000 · RR
BUPROPION AS AN ADJUNCT TO THE NICOTINE PATCH PLUS CBT$336,222
R01 · FY2000 · DA
BEHAVIORAL EFFECTS OF ACUTE TRYPTOPHAN DEPLETION IN DEPRESSED PATIENTS$575
M01 · FY2000 · RR
FLUOXETINE, PAROXETINE, &SERTRALINE IN TREAT OF MAJOR DEPRESSION$575
M01 · FY2000 · RR